BioSpace News Archive

Facilities in The Schrödinger Building to bring together AI experts and biologists

First commercially available reference standard for microsatellite instability (MSI) testing

Hawaii Biotech Inc. will continue its development of an anti-toxin drug for anthrax in humans with a recently awarded contract from the National Institute of Allergy and Infectious Diseases (NIAID), a federal government agency.

- Partner MD Anderson Cancer Center will present preclinical data on HDP-101 for effective 17p deletion in multiple myeloma in an oral presentation

Esperion today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2018.

Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion.

Leerink Holdings is the Boston-based parent company of Leerink Partners. Leerink Partners is an investment bank focused on healthcare and life sciences.

Stallergenes Greer today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the extension of the indication for Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract), an allergy immunotherapy sublingual tablet, to treat patients ages five to nine with grass pollen-induced allergic rhinitis.

FSD Pharma Inc. announced today the appointment of David Urban to the Company’s Board of Directors.

The Avamere Family of Companies announced today a strategic organization change to move from a company of individual entities (Avamere Living, Infinity Rehab and Signature Healthcare At Home) to a cohesive post-acute and community-based health care system.